Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRIXADI vs CARISOPRODOL AND ASPIRIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Buprenorphine is a partial agonist at mu-opioid receptors and an antagonist at kappa-opioid receptors, reducing opioid withdrawal symptoms and cravings.
Carisoprodol is a centrally acting muscle relaxant that modulates GABA-A receptor activity and may act as a weak partial agonist at the central nervous system. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis, which results in analgesic, antipyretic, and anti-inflammatory effects.
FDA-approved for the treatment of opioid use disorder (opioid dependence) as part of a comprehensive treatment plan
Relief of discomfort associated with acute painful musculoskeletal conditions
Brixadi (buprenorphine) extended-release injection for subcutaneous use: Patients on transmucosal buprenorphine products, after a single dose of 8-24 mg transmucosal buprenorphine, administer Brixadi as a subcutaneous injection once weekly: 8 mg/week for patients on 8-16 mg/day transmucosal buprenorphine, 16 mg/week for patients on 12-24 mg/day, 24 mg/week for patients on 16-24 mg/day. Alternatively, monthly injection: 64 mg/month for patients on 8-16 mg/day, 96 mg/month for patients on 12-24 mg/day, 128 mg/month for patients on 16-24 mg/day.
1-2 tablets (carisoprodol 200 mg / aspirin 325 mg) orally 4 times daily.
Terminal half-life approximately 470–500 hours (~20 days) following intramuscular injection, allowing weekly or monthly dosing.
Carisoprodol: 1.5-2 hours (terminal half-life), but active metabolite meprobamate has half-life of 9-12 hours, contributing to prolonged sedation. Aspirin: 15-20 minutes (parent drug); salicylate: 2-3 hours at low doses, 15-30 hours at high doses due to saturable hepatic metabolism.
Primarily metabolized by CYP3A4 to norbuprenorphine (active metabolite) via N-dealkylation; also undergoes glucuronidation.
Carisoprodol is N-deacetylated via CYP2C19 to meprobamate, a schedule IV controlled substance. Aspirin is hydrolyzed to salicylic acid in the liver and gastrointestinal tract.
Primarily fecal (80–90%) as unchanged drug; renal elimination accounts for <5% of the dose.
Carisoprodol: Renal excretion of metabolites (hydroxycarisoprodol, meprobamate) and <1% unchanged. Aspirin: Renal excretion of salicylate and metabolites (salicyluric acid, gentisic acid); ~80% renal, with dose-dependent elimination via first-order and Michaelis-Menten kinetics.
Approximately 99% bound to plasma proteins, primarily albumin and alpha1-acid glycoprotein.
Carisoprodol: ~60% bound to albumin. Aspirin: 80-90% bound to albumin (salicylate); highly protein-bound at therapeutic concentrations.
Volume of distribution is very large, approximately 500–1000 L (about 5–10 L/kg in a 70 kg individual), indicating extensive tissue binding and sequestration.
Carisoprodol: ~0.7 L/kg (large Vd, extensive tissue distribution). Aspirin: ~0.15 L/kg (salicylate; low Vd, primarily in extracellular fluid). Clinical meaning: Carisoprodol distributes into CNS and muscle; aspirin remains largely in plasma and interstitial space.
Intramuscular injection: bioavailability is nearly 100% due to limited first-pass metabolism; oral bioavailability is <5% due to extensive first-pass metabolism.
Oral: Carisoprodol: ~90% (well absorbed). Aspirin: ~40-50% (presystemic hydrolysis in GI mucosa and liver; rectal: 100% absorbed, but avoids first-pass).
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m2) or end-stage renal disease, use with caution and consider dose reduction due to potential accumulation; specific dosing guidelines not established.
e GFR 30-59 m L/min: avoid or reduce dose; e GFR <30 m L/min: contraindicated.
Child-Pugh Class A (mild): No adjustment. Child-Pugh Class B (moderate): Start at lower dose and titrate cautiously; maximum recommended weekly dose 16 mg, monthly dose 96 mg. Child-Pugh Class C (severe): Not recommended due to lack of data.
Child-Pugh Class A: caution; Class B or C: contraindicated.
Not approved for use in pediatric patients; safety and efficacy not established.
Not recommended for pediatric patients under 12 years of age. For older adolescents, weight-based dosing of aspirin 10-15 mg/kg/dose every 4-6 hours (max 80 mg/kg/day) and carisoprodol 5-10 mg/kg/dose three times daily; avoid routine use due to risk of Reye's syndrome.
No specific dose adjustments recommended; geriatric patients may have increased sensitivity and should be monitored closely for sedation, respiratory depression, and QTc prolongation. Initiate at lower end of dosing range if severe renal or hepatic impairment present.
Initiate at lowest effective dose; monitor for CNS depression, renal function, and bleeding risk. Avoid in patients with significant renal impairment or peptic ulcer disease.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of harm or death from accidental ingestion; concomitant use of benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
None.
May cause respiratory depression; risk of abuse potential; need to monitor for hepatic dysfunction; adrenal insufficiency; QT prolongation; precipitation of withdrawal if initiated too soon after full agonist opioids; impairment of mental/physical abilities.
Dependence and withdrawal: Carisoprodol may cause dependence and withdrawal symptoms.,Sedation and CNS depression: Additive effects with alcohol and other CNS depressants.,Reye's syndrome: Aspirin use in children and teenagers with viral illness.,Gastrointestinal bleeding: Aspirin increases risk of GI bleeding.,Hypersensitivity reactions: Anaphylaxis, angioedema.
Hypersensitivity to buprenorphine; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; concurrent use of monoamine oxidase inhibitors (MAOIs) or use within 14 days.
Hypersensitivity to carisoprodol or aspirin.,Children and teenagers with viral infections (Reye's syndrome risk).,Active peptic ulcer disease or GI bleeding.,Severe hepatic impairment.,History of asthma induced by aspirin or NSAIDs.,Concomitant use with meprobamate-containing products.
No specific food interactions are reported for BRIXADI. However, patients should avoid alcohol and grapefruit juice as they may potentiate CNS depression or alter metabolism (grapefruit inhibits CYP3A4, which metabolizes buprenorphine, potentially increasing levels). Advise a balanced diet without restrictions beyond general health recommendations.
Avoid alcohol. Take with food or milk to reduce gastrointestinal irritation. Avoid high-tyramine foods (e.g., aged cheese, cured meats) as aspirin may potentiate tyramine effects.
Insufficient human data; animal studies show no teratogenicity at clinically relevant doses. Risk cannot be excluded; use only if benefit outweighs risk.
First trimester: Aspirin associated with increased risk of neural tube defects and gastroschisis; carisoprodol limited data. Second and third trimesters: Aspirin use increases risk of premature closure of ductus arteriosus and oligohydramnios; carisoprodol not well studied but may cause neonatal withdrawal. Avoid in third trimester due to aspirin's antiprostaglandin effects.
Unknown if excreted in human milk; no M/P ratio available. Consider risks and benefits; avoid breastfeeding if possible.
Aspirin and carisoprodol are excreted into breast milk. M/P ratio for aspirin is approximately 0.6-0.9; carisoprodol M/P ratio not established. Risk of Reye syndrome with aspirin, neonatal salicylate accumulation, and sedation from carisoprodol. Use not recommended during breastfeeding.
No standard dose adjustment; increased clearance in pregnancy may require dose titration to effect. Monitor for withdrawal or inadequate response.
Pregnancy increases clearance of aspirin and carisoprodol; however, avoid use due to fetal risks. No recommended dose adjustments; contraindicated, especially in third trimester.
BRIXADI (buprenorphine extended-release) is a monthly subcutaneous depot formulation for opioid use disorder (OUD). Initiate only after patient is stabilized on transmucosal buprenorphine (e.g., 8–24 mg/day for at least 7 days). Do not use in opioid-naive patients due to risk of precipitated withdrawal. Administer subcutaneously in the abdomen; avoid intramuscular or intravenous injection. Monitor injection site for nodules, granulomas, or infection. Concomitant use with benzodiazepines or CNS depressants requires careful monitoring due to additive respiratory depression. Liver function tests should be monitored periodically due to risk of hepatic injury. BRIXADI contains buprenorphine as the free base, not salt; dose strengths (64 mg, 96 mg, 128 mg) are not equivalent to other buprenorphine formulations. Upon discontinuation, patients may experience prolonged withdrawal due to slow release over weeks.
Carisoprodol is metabolized to meprobamate, a controlled substance; monitor for abuse potential. Aspirin increases bleeding risk; avoid in children with viral illness due to Reye's syndrome. Combination may cause CNS depression and impaired motor function. Use with caution in renal impairment.
BRIXADI is a once-monthly injection to treat opioid dependence and must be given by a healthcare provider only.,Do not attempt to self-administer or remove the injection. The medicine is released slowly over one month.,Notify your doctor immediately if you have trouble breathing, excessive drowsiness, or severe dizziness, especially when combined with alcohol or sedatives.,Avoid use of other opioids (prescription or illicit), as serious side effects including coma or death may occur.,Report any signs of liver problems: dark urine, yellowing skin/eyes, persistent nausea, or abdominal pain.,The injection site may become red, swollen, or painful; contact your doctor if these persist or worsen.,Do not stop BRIXADI suddenly; withdrawal symptoms may occur and can be prolonged.,Keep out of reach of children and pets; accidental exposure can be fatal.
Do not drive or operate machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Take with food or milk to reduce stomach upset.,Do not use in children or teenagers with flu-like symptoms or chickenpox due to risk of Reye's syndrome.,Report signs of bleeding (easy bruising, black stools, vomiting blood) or allergic reactions (rash, swelling, difficulty breathing).,Rapid discontinuation may cause withdrawal symptoms (anxiety, insomnia, muscle twitching).
No interactions on record
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRIXADI vs CARISOPRODOL AND ASPIRIN, answered by our medical review team.
BRIXADI is a Opioid Partial Agonist that works by Buprenorphine is a partial agonist at mu-opioid receptors and an antagonist at kappa-opioid receptors, reducing opioid withdrawal symptoms and cravings.. CARISOPRODOL AND ASPIRIN is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting muscle relaxant that modulates GABA-A receptor activity and may act as a weak partial agonist at the central nervous system. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis, which results in analgesic, antipyretic, and anti-inflammatory effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRIXADI and CARISOPRODOL AND ASPIRIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRIXADI is: Brixadi (buprenorphine) extended-release injection for subcutaneous use: Patients on transmucosal buprenorphine products, after a single dose of 8-24 mg transmucosal buprenorphine, administer Brixadi as a subcutaneous injection once weekly: 8 mg/week for patients on 8-16 mg/day transmucosal buprenorphine, 16 mg/week for patients on 12-24 mg/day, 24 mg/week for patients on 16-24 mg/day. Alternatively, monthly injection: 64 mg/month for patients on 8-16 mg/day, 96 mg/month for patients on 12-24 mg/day, 128 mg/month for patients on 16-24 mg/day.. The standard adult dose of CARISOPRODOL AND ASPIRIN is: 1-2 tablets (carisoprodol 200 mg / aspirin 325 mg) orally 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRIXADI and CARISOPRODOL AND ASPIRIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRIXADI is classified as Category C. Insufficient human data; animal studies show no teratogenicity at clinically relevant doses. Risk cannot be excluded; use only if benefit outweighs risk.. CARISOPRODOL AND ASPIRIN is classified as Category A/B. First trimester: Aspirin associated with increased risk of neural tube defects and gastroschisis; carisoprodol limited data. Second and third trimesters: Aspirin use increases risk. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.